ArticleApplied biochemistry and biotechnology2026
Neuroprotective Effect of Lemon-derived Exosome-like Nanovesicles On Transient Global Cerebral Ischemia/reperfusion Injury in Rat.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke poses a significant global health challenge, resulting in severe cognitive impairments. Although thrombolytic therapy is the primary treatment, its narrow therapeutic window and risk of hemorrhagic complications limit its clinical utility. Moreover, the restoration of blood flow (reperfusion) can paradoxically exacerbate tissue damage. This process, known as ischemia/reperfusion (I/R) injury, occurs through complex pathological cascades. In this study, we evaluated the therapeutic efficacy of lemon-derived exosome-like nanovesicles (LELNs) in a rat model of global cerebral I/R injury. Male Wistar rats were divided into the following groups: Sham + PBS, I/R + PBS, I/R + Quercetin, and I/R + LELNs (10, 25, and 50 mg/kg). On day seven post-injury, behavioral assessments—including spatial memory, working memory, and anxiety-like behavior—were conducted using the Morris water maze, Y-maze, and open field tests. Based on these behavioral results, the 25 mg/kg LELNs dose was identified as optimal and selected for subsequent biochemical and molecular analyses. Our biochemical and molecular analyses assessed a comprehensive panel of parameters, including blood–brain barrier (BBB) permeability, microglial polarization (M1 and M2 phenotypes), inflammatory and anti-inflammatory cytokine profiles, oxidative stress markers (nitric oxide and superoxide dismutase), and GLT-1 expression. In summary, 25 mg/kg LELNs confer neuroprotection in cerebral I/R injury by reprogramming microglial polarization from an M1 to an M2 phenotype. This central mechanism orchestrates a protective cascade that attenuates excitotoxicity, neuroinflammation, oxidative stress, and blood–brain barrier disruption, positioning LELNs as a promising multi-targeted therapy for ischemic stroke.
Indexed as
Identifiers
41665858What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.